-
公开(公告)号:US20050075285A1
公开(公告)日:2005-04-07
申请号:US10467554
申请日:2002-02-07
申请人: Barbara Bour , John Chicca , Blake Denison , Frances Yen-Potin , Bernard Bihain , Stephane Bejanin , Hiroaki Tanaka , Severin Jobert , Jean-Yves Giordano , Jean-Baptiste Dumas Milne Edwards
发明人: Barbara Bour , John Chicca , Blake Denison , Frances Yen-Potin , Bernard Bihain , Stephane Bejanin , Hiroaki Tanaka , Severin Jobert , Jean-Yves Giordano , Jean-Baptiste Dumas Milne Edwards
CPC分类号: C07K14/5759 , A61K38/00 , C07K14/775 , Y10S514/909
摘要: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to: obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.
摘要翻译: 本发明涉及代谢研究领域。 代谢紊乱,如肥胖,是一个严重而广泛的公共卫生问题。 已经鉴定出GSSP4多肽被认为在治疗代谢紊乱中是有益的。 这些化合物应有效降低胆固醇水平,体重,体脂肪,以及治疗与代谢有关的疾病和病症。 预期通过本发明的方法治疗的代谢相关疾病或病症包括但不限于:肥胖症,高脂血症,高胆固醇血症,动脉粥样硬化,糖尿病,葡萄糖不耐受,胰岛素抵抗和高血压。
-
公开(公告)号:US07223727B2
公开(公告)日:2007-05-29
申请号:US10467554
申请日:2002-02-07
申请人: Barbara Chicca , John Chicca , Blake Denison , Frances Yen-Potin , Bernard Bihain , Stephane Bejanin , Hiroaki Tanaka , Severin Jobert , Jean-Yves Giordano , Jean-Baptiste Dumas Milne Edwards
发明人: Barbara Chicca , John Chicca , Blake Denison , Frances Yen-Potin , Bernard Bihain , Stephane Bejanin , Hiroaki Tanaka , Severin Jobert , Jean-Yves Giordano , Jean-Baptiste Dumas Milne Edwards
IPC分类号: A61K38/00
CPC分类号: C07K14/5759 , A61K38/00 , C07K14/775 , Y10S514/909
摘要: The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders include, but are not limited to, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.
摘要翻译: 本发明涉及代谢研究领域。 代谢紊乱,如肥胖,是一个严重而广泛的公共卫生问题。 已经鉴定出GSSP4多肽被认为在治疗代谢紊乱中是有益的。 这些化合物应有效降低胆固醇水平,体重,体脂肪,以及治疗与代谢有关的疾病和病症。 与代谢相关的疾病或病症包括但不限于肥胖症,高脂血症,高胆固醇血症,动脉粥样硬化,糖尿病,葡萄糖不耐症,胰岛素抵抗和高血压。
-